scholarly journals Metabiotics: prospects, challenges and opportunities

2019 ◽  
Vol 2 (13) ◽  
pp. 43-48
Author(s):  
B. A. Shenderov ◽  
E. I. Tkachenko ◽  
M. M. Zakharchenko ◽  
A. V. Sinitsa
Keyword(s):  
Personalized Medicine ◽  
Chemical Structure ◽  
Metabolic Diseases ◽  
Fermented Foods ◽  
Structural Components ◽  
Physiological Regulator ◽  
Challenges And Opportunities ◽  
Symbiotic Microbiota ◽  
Modern Condition ◽  
Living Bacteria

In this review authors discuss modern condition of treatment and prophylaxis of human metabolic diseases associated with microecological imbalance of intestinal symbiotic microbiota. Now the most frequently for these aims various probiotic nutrient additives and functional fermented foods prepared on the basis of living bacteria have been used. Unfortunately such probiotics have not possessed the real effectiveness and are not completely safe. Instead of traditional commercially available living probiotics the authors suggest to use novel microecological means (metabiotics) that are structural components of probiotic bactrerial strains, and/or their metabolites and/or signaling molecules with known chemical structure. Metabiotics can optimize host‑specific physiological, regulator, metabolic and/or hormone/behavior functions and reactions. Metabiotics possess some advantages in future personalized medicine because they have exact chemical structure, well dosed, safe and long shelf‑life.

scholarly journals Pharmacogenetics of carbamazepine

2020 ◽  
Vol 11 (4) ◽  
pp. 364-378 ◽  
Author(s):  
N. A. Shnayder ◽  
E. N. Bochanova ◽  
D. V. Dmitrenko ◽  
R. F. Nasyrova
Keyword(s):  
Personalized Medicine ◽  
Mental Disorders ◽  
Conflict Of Interest ◽  
Chemical Structure ◽  
Tricyclic Antidepressants ◽  
Neurological Diseases

Carbamazepine (CMZ) is a drug from the group of anticonvulsants, similar in chemical structure to tricyclic antidepressants. CMZ is widely used for mental disorders and neurological diseases. The lecture discusses the safety of CMZ in respect to personalized medicine, while considering the pharmacogenetic profile of the patient.The authors declare about the absence of conflict of interest with respect to this publication. All authors contributed equally to this article.

Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities

Drugs ◽  
2019 ◽  
Vol 79 (11) ◽  
pp. 1187-1197 ◽  
Author(s):  
Jonas Petersen ◽  
Kristian Strømgaard ◽  
Bente Frølund ◽  
Christoffer Clemmensen
Keyword(s):  
Metabolic Diseases ◽  
Challenges And Opportunities

Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine

2020 ◽  
Author(s):  
Radia Hassan ◽  
Imane Allali ◽  
Francis E Agamah ◽  
Samar S M Elsheikh ◽  
Nicholas E Thomford ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Drug Targets ◽  
Drug Response ◽  
Association Studies ◽  
Human Microbiome ◽  
Drug Efficacy ◽  
Genome Wide Association Studies ◽  
Therapeutic Drugs ◽  
Complex Interactions ◽  
Challenges And Opportunities

Abstract Researchers have long been presented with the challenge imposed by the role of genetic heterogeneity in drug response. For many years, Pharmacogenomics and pharmacomicrobiomics has been investigating the influence of an individual’s genetic background to drug response and disposition. More recently, the human gut microbiome has proven to play a crucial role in the way patients respond to different therapeutic drugs and it has been shown that by understanding the composition of the human microbiome, we can improve the drug efficacy and effectively identify drug targets. However, our knowledge on the effect of host genetics on specific gut microbes related to variation in drug metabolizing enzymes, the drug remains limited and therefore limits the application of joint host–microbiome genome-wide association studies. In this paper, we provide a historical overview of the complex interactions between the host, human microbiome and drugs. While discussing applications, challenges and opportunities of these studies, we draw attention to the critical need for inclusion of diverse populations and the development of an innovative and combined pharmacogenomics and pharmacomicrobiomics approach, that may provide an important basis in personalized medicine.

scholarly journals The role of epigenetics in personalized medicine: challenges and opportunities

2015 ◽  
Vol 8 (S1) ◽  
Author(s):  
Mahmood Rasool ◽  
Arif Malik ◽  
Muhammad Imran Naseer ◽  
Abdul Manan ◽  
Shakeel Ahmed Ansari ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Challenges And Opportunities
Sign in / Sign up

Export Citation Format

Share Document